

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Search Results -

| Term | Documents |
|--|-------------|
| H2F.USPT,PGPB. | 8 |
| H2FS | 0 |
| I2R.USPT,PGPB. | 38 |
| I2RS | 0 |
| 3D1.USPT,PGPB. | 165 |
| 3D1S | 0 |
| ANTIBOD\$ | 0 |
| ANTIBOD.USPT,PGPB. | 229 |
| ANTIBODAY.USPT,PGPB. | 1 |
| ANTIBODEES.USPT,PGPB. | 1 |
| | |
| ANTIBOD\$(ANTIBODY/ADA).USPT,PGPB. | pickup term |
| ((H2F OR I2R OR 3D1) SAME (ANTIBOD\$ OR HYBRIDOMA\$ OR IMMUNOGLOBULIN\$)).USPT,PGPB. | 8 |

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

(H2F or I2R or 3D1) same (antibod\$ or
hybridoma\$ or immunoglobulin\$)

[Clear](#)**Search History**

Today's Date: 6/23/2001

| <u>DB Name</u> | <u>Query</u> | <u>Hit Count</u> | <u>Set Name</u> |
|----------------|---|------------------|-----------------|
| USPT,PGPB | (H2F or I2R or 3D1) same (antibod\$ or hybridoma\$ or immunoglobulin\$) | 8 | <u>L1</u> |

WEST☐ Generate Collection

L1: Entry 1 of 8

File: USPT

Mar 6, 2001

DOCUMENT-IDENTIFIER: US 6197524 B1

TITLE: Methods for detecting, identifying, isolating, and selectively labelling and targeting TH1 lymphocyte by means of the LAG-3 protein

DEPR:

Detection of soluble LAG-3 in the supernatants of T-cell clones was performed by an appropriate ELISA based on the use of a recombinant soluble LAG-3 derived molecule (sLAG-3D1-D2). sLAG-3D1-D2 was obtained from PCR amplified DNA fragment encoding for the two first immunoglobulin-like domains of LAG-3 and subcloned into the pCLH3AXSV2DHFR expression vector (Cole et al., 1993). The construct was used to transfect a DHFR deficient CHO cell line (DUKX-B11) (Urlaub and Chasin, 1980). The sLAG-3D1-D2-producing CHO cells were cultured in Wheaton bioreactor and sLAG-3D1-D2 molecule purified by capture step on fast SP-Sepharose column followed by immunopurification on a 17B4 mAb-Poros EP column. The resulting protein was found to be >90% pure by RP-HPLC and SDS-PAGE. For the assay, plate wells were coated with anti-LAG-3 (11E3; 10. μ g/ml on 0.2 M carbonate buffer, pH 9.6) mAb and then incubated for 12 hr with test samples or different dilutions (from 0.12 to 25 ng/ml) of sLAG-3D1-D2. After washings, biotinylated anti-LAG-3 (17B4) mAb (0.5 μ g/ml) was added for additional 2 hr, the plates stained with substrate solution, and the reaction read at 492 nm.

WEST

Generate Collection

L1: Entry 3 of 8

File: USPT

Aug 29, 2000

DOCUMENT-IDENTIFIER: US 6110463 A

TITLE: Anti-Cryptosporidium parvum preparations

DEPR:

Hybridomas secreting mAbs listed in the first column of Table 4 were separately propagated in BALB/c mice and ascites fluid samples containing the mAbs collected using standard laboratory methods. These mAb preparations were administered to neonatal BALB/c mice as pools of ascites fluid to test the in vivo neutralizing capacity of the preparations according to the method described under Example 5. The volume of ascites fluid administered to neonatal mice in this procedure was held constant at 150 .mu.l. Equal volumes of different ascites fluid samples were mixed to create preparations of mAb combinations. A pool or collection of mAbs HL113 (IgM), HL245 (IgG.sub.3) and HL296 (IgG.sub.1), all having irrelevant binding specificities, served as a negative control in the procedure. A second pool included mAbs 18.44, C6B6, C4A1, 2B4, 3D1, 3E2 and M23A1, all having binding specificities for epitopes disposed on *C. parvum*. In this procedure, 8-10 mice were used for each test group.

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

| Term | Documents |
|--|-----------|
| H2F.USPT,PGPB. | 8 |
| H2FS | 0 |
| I2R.USPT,PGPB. | 38 |
| I2RS | 0 |
| 3D1.USPT,PGPB. | 165 |
| 3D1S | 0 |
| CHIMERIC.USPT,PGPB. | 10178 |
| CHIMERICS.USPT,PGPB. | 60 |
| CHIMAERIC.USPT,PGPB. | 592 |
| CHIMAERICS.USPT,PGPB. | 2 |
| ((H2F OR I2R OR 3D1) SAME (CHIMERIC OR CHIMAERIC OR HUMANIZ\$ OR HUMANIS\$)).USPT,PGPB. | 0 |

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

(H2F or I2R or 3D1) same (chimeric or
chimaeric or humaniz\$ or humanis\$)

[Clear](#)**Search History**

Today's Date: 6/23/2001

| <u>DB Name</u> | <u>Query</u> | <u>Hit Count</u> | <u>Set Name</u> |
|----------------|--|------------------|-----------------|
| USPT,PGPB | (H2F or I2R or 3D1) same (chimeric or chimaeric or humaniz\$ or humanis\$) | 0 | <u>L2</u> |
| USPT,PGPB | (H2F or I2R or 3D1) same (antibod\$ or hybridoma\$ or immunoglobulin\$) | 8 | <u>L1</u> |